Pete England
About Pete England
Pete England serves as the Vice President of Global Surgical Marketing at Sight Sciences, Inc., a position he has held since 2021. He also contributes to the Angelman Syndrome Foundation as a board member and has extensive experience in the medical device and healthcare sectors.
Work at Sight Sciences
Pete England serves as the Vice President of Global Surgical Marketing at Sight Sciences, Inc. since 2021. In this role, he is responsible for overseeing marketing strategies and initiatives related to surgical products. His tenure at Sight Sciences has been marked by a focus on innovation and market penetration within the surgical sector.
Board Membership at Angelman Syndrome Foundation
Since 2020, Pete England has been a member of the Board of Directors at the Angelman Syndrome Foundation. His involvement supports the foundation's mission to advance research and provide resources for individuals affected by Angelman syndrome. He contributes to strategic discussions aimed at enhancing the foundation's outreach and impact.
Previous Experience in Eye Care and Health Marketing
Prior to his current roles, Pete England held various positions in the healthcare marketing sector. He worked at 2e Creative as Vice President of Strategic Partnerships and Head of Eye Care from 2019 to 2020. He also served as SVP of Strategic Partnerships at Fishawack Health for a brief period in 2020. His experience includes significant roles at Alcon, where he was the Commercial Head for US Surgical Glaucoma from 2016 to 2019.
Education and Expertise
Pete England studied at Texas Christian University from 1996 to 2000, where he gained foundational knowledge that supports his career in healthcare marketing and strategic partnerships. His educational background complements his extensive experience in the medical device and pharmaceutical industries.
Achievements in Glaucoma Market
During his time at Alcon, Pete England successfully launched the first-ever pre-loaded MIGS device shortly after FDA approval, achieving significant market conversion. He managed a $360 million franchise of glaucoma pharmaceutical therapies, consistently exceeding brand share and revenue objectives. His strategic initiatives have contributed to advancements in the glaucoma treatment market.